Published in Diabetes Metab on December 01, 2004
Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS One (2013) 0.96
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag (2008) 0.94
Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes (2012) 0.83
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. J Diabetes Res (2014) 0.80
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag (2008) 0.79
Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2). Sci Rep (2015) 0.77
Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function. J Diabetes Investig (2016) 0.75
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia (2008) 4.62
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (2001) 3.60
End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis (1999) 3.00
Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia (2011) 1.94
Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia (2002) 1.93
One-year efficacy and safety of Web-based follow-up using cellular phone in type 1 diabetic patients under insulin pump therapy: the PumpNet study. Diabetes Metab (2007) 1.88
Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia (2011) 1.85
Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med (2006) 1.84
Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res (2000) 1.78
Intensive attention improves glycaemic control in insulin-dependent diabetes without further advantage from home blood glucose monitoring: results of a controlled trial. Br Med J (Clin Res Ed) (1982) 1.61
Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. J Immunol (1994) 1.60
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab (2008) 1.59
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia (2004) 1.57
Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol (2000) 1.53
Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax (1987) 1.48
Early disturbances of ambulatory blood pressure load in normotensive type I diabetic patients with microalbuminuria. Diabetes Care (1992) 1.48
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab (2015) 1.47
Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia (1982) 1.46
Deleterious effect of dithizone-DMSO staining on insulin secretion in rat and human pancreatic islets. Pancreas (1994) 1.45
A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Res Clin Pract (2011) 1.44
The UK Diabetes Dataset: a standard for information exchange. Diabetes Audit Working Group of the Research Unit of the Royal College of Physicians. British Diabetic Association. Diabet Med (1995) 1.42
Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest (1997) 1.40
Obesity, haemostasis and the fibrinolytic system. Obes Rev (2002) 1.40
Diabetes care in general practice: an approach to audit of process and outcome. Br J Gen Pract (1993) 1.40
Hepatic nuclear factor 1-alpha directs nucleosomal hyperacetylation to its tissue-specific transcriptional targets. Mol Cell Biol (2001) 1.39
Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. Diabet Med (2008) 1.38
[Therapy of diabetes in adults using Glibornurid. Results and clinical studies]. Dtsch Med Wochenschr (1973) 1.38
A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Diabet Med (1984) 1.37
Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia (1987) 1.36
Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med (2006) 1.33
Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed) (1981) 1.32
Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med (2001) 1.31
Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) (2006) 1.22
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med (2002) 1.20
Diagnostic confusion in diabetes with persistence of fetal haemoglobin. BMJ (1992) 1.20
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res (1999) 1.19
Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab (2010) 1.19
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab (2012) 1.19
Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care (2000) 1.17
Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care (1999) 1.17
Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4. Diabetologia (2008) 1.14
Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol (2003) 1.13
Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes (1999) 1.13
Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care (2000) 1.12
Reduced hepatic insulin extraction in obesity: relationship with plasma insulin levels. J Clin Endocrinol Metab (1983) 1.10
A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract (2010) 1.10
Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol (1999) 1.10
Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed) (1983) 1.09
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia (2005) 1.09
4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol (1999) 1.09
Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control. Diabetes Res Clin Pract (2006) 1.08
The 1997 ADA diabetes diagnostic categories: impact on employees' annual medical examination. Diabet Med (1999) 1.08
Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med (2007) 1.08
A dataset to allow exchange of information for monitoring continuing diabetes care. The Diabetes Audit Working Group. Diabet Med (1993) 1.08
4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes (1998) 1.07
Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Horm Metab Res (2003) 1.06
Vitamin E improves the free radical defense system potential and insulin sensitivity of rats fed high fructose diets. J Nutr (1997) 1.06
Lipid peroxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur J Clin Nutr (1995) 1.06
Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes (1999) 1.06
An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes (1999) 1.04
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab (2003) 1.04
Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab (2007) 1.02
Enzymatic, metabolic and secretory patterns in human islets of type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1994) 1.01
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med (2000) 1.00
Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab (2012) 1.00
Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women. Int J Obes Relat Metab Disord (2001) 1.00
Diagnosing the undiagnosed with diabetes. BMJ (1994) 1.00
Prevalence of diabetes and cardiovascular risk factors of industrial area in southern Poland. Exp Clin Endocrinol Diabetes (2009) 1.00
Influence of metabolic disturbances of diabetes mellitus on serum CA 19-9 tumor marker. Diabete Metab (1991) 1.00
Inhibition of gluconeogenesis in isolated rat hepatocytes after chronic treatment with phenobarbital. Biochem J (1991) 0.99
Prevalence of morning hyperglycaemia: determinants of fasting blood glucose concentrations in insulin-treated diabetics. Diabet Med (1985) 0.99
Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies. Diabetologia (1985) 0.99
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med (2006) 0.99
A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. Diabetes Care (1984) 0.99
Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med (2013) 0.98
Human insulin. Clin Endocrinol Metab (1982) 0.98
High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. J Clin Endocrinol Metab (1999) 0.98
Expression of GLUT-2 antisense RNA in beta cells of transgenic mice leads to diabetes. J Biol Chem (1994) 0.97
Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommendations. Diabetes Metab (2004) 0.97
Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab (2008) 0.97
Pancreatic islet GLUT2 glucose transporter mRNA and protein expression in humans with and without NIDDM. Diabetes (1995) 0.97
A laboratory trial of two new blood-glucose reflectance meters featuring automatic external calibration. Ann Clin Biochem (1984) 0.97
P2 receptor agonists stimulate insulin release from human pancreatic islets. Pancreas (2001) 0.97
Identifying the impact of diabetes research. Diabet Med (2006) 0.97
Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab (2009) 0.97
Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Diabet Med (1990) 0.96
Multicenter randomized evaluation of a nutritional education software in obese patients. Diabetes Metab (2001) 0.96
Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes. Diabet Med (2010) 0.96
Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology (1991) 0.96
Auditory function in young patients with type 1 diabetes mellitus. Diabetes Res Clin Pract (1991) 0.95
Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia (1993) 0.95
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]. Rev Med Liege (2010) 0.95
Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. Diabetes Care (1982) 0.95
Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets. Diabetologia (1998) 0.94
Protection of pancreatic INS-1 β-cells from glucose- and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin. Cell Death Dis (2011) 0.94